Audio is streamed from the publisher.
Show notes
Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and is easier to scale for widespread use. Dave highlights the ongoing questions that linger about the drugs approval as it relates to liver safety.